drugset / Trial / NCT05100251
Clinical Trial of WBC100 on Advanced Solid Tumor
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I clinical study of WBC100 in patients with advanced solid tumor.
Timeline
- Start
- 2021-12-17
- Primary completion
- 2026-01-06
- Completion
- 2026-01-06
Outcome
Outcome not reported
Stopped (Business): “sponsor's decision to change development strategy (the QOD cohort was completed).”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WBC100 | Unknown | 0.5 mg | — |
| Subject | WBC100 | Unknown | 1 mg | — |
| Subject | WBC100 | Unknown | 1.5 mg | — |
| Subject | WBC100 | Unknown | 2 mg | — |
| Subject | WBC100 | Unknown | 2.5 mg | — |
| Subject | WBC100 | Unknown | 3 mg | — |
| Subject | WBC100 | Unknown | 3.5 mg | — |
| Subject | WBC100 | Unknown | 4 mg | — |
| Subject | WBC100 | Unknown | 4.5 mg | — |